XBRANE — Xbrane Biopharma AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK35.70bn
- SEK35.71bn
- SEK198.72m
Annual cashflow statement for Xbrane Biopharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | — | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -226 | -188 | -173 | -388 | -255 |
| Depreciation | |||||
| Non-Cash Items | -0.319 | -6.35 | 9.27 | 101 | 90.7 |
| Discontinued Operations | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -18.6 | -38.4 | -30.7 | -119 | 30.7 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -238 | -220 | -194 | -406 | -133 |
| Capital Expenditures | -3.85 | -77.3 | -60.1 | -16.8 | -52.2 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | -3.85 | -77.3 | -60.1 | -16.8 | -52.2 |
| Financing Cash Flow Items | -20.6 | -24.2 | -13.3 | -0.963 | -37.5 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 323 | 349 | 149 | 299 | 244 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 78.9 | 53.3 | -101 | -129 | 58.9 |